New drug combo tested to keep ovarian cancer at bay longer
NCT ID NCT01081951
Summary
This study tested whether adding a drug called olaparib to standard chemotherapy (paclitaxel and carboplatin) works better than chemotherapy alone for controlling advanced ovarian cancer that had previously responded to platinum drugs. It involved 162 patients whose cancer had returned after being controlled for at least 6 months. The main goal was to see if the combination could delay the cancer from getting worse for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Stanford, California, 94305, United States
-
Research Site
West Hollywood, California, 90048, United States
-
Research Site
Orlando, Florida, 32806, United States
-
Research Site
Indianapolis, Indiana, 46202, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
New York, New York, 10016, United States
-
Research Site
Portland, Oregon, 97227-1191, United States
-
Research Site
Parkville, 3050, Australia
-
Research Site
Randwick, 2031, Australia
-
Research Site
Brussels, 1090, Belgium
-
Research Site
Leuven, 3000, Belgium
-
Research Site
Namur, 5000, Belgium
-
Research Site
Wilrijk, 2610, Belgium
-
Research Site
Vancouver, British Columbia, V5Z 4E6, Canada
-
Research Site
Hamilton, Ontario, L8V 5C2, Canada
-
Research Site
Toronto, Ontario, M4N 3M5, Canada
-
Research Site
Toronto, Ontario, M5G 2M9, Canada
-
Research Site
Québec, Quebec, G1R 2J6, Canada
-
Research Site
Sherbrooke, Quebec, J1H 5N4, Canada
-
Research Site
Brno, 625 00, Czechia
-
Research Site
Brno, 656 53, Czechia
-
Research Site
Hradec Králové, 500 05, Czechia
-
Research Site
Olomouc, 775 20, Czechia
-
Research Site
Prague, 120 00, Czechia
-
Research Site
Essen, 45147, Germany
-
Research Site
Frankfurt, 60590, Germany
-
Research Site
Hamburg, 20246, Germany
-
Research Site
München, 81675, Germany
-
Research Site
Solingen, 42653, Germany
-
Research Site
Genova, 16132, Italy
-
Research Site
Milan, 20141, Italy
-
Research Site
Monza, 20052, Italy
-
Research Site
Torino, 10126, Italy
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Fukuoka, 811-1395, Japan
-
Research Site
Matsuyama, 791-0280, Japan
-
Research Site
Morioka, 028-3695, Japan
-
Research Site
Shinjuku-ku, 160-8582, Japan
-
Research Site
Yamagata, 990-9585, Japan
-
Research Site
Yonago-shi, 683-8504, Japan
-
Research Site
Amsterdam, 1066 CX, Netherlands
-
Research Site
Amsterdam, 1105 AZ, Netherlands
-
Research Site
Nijmegen, 6525 GA, Netherlands
-
Research Site
Rotterdam, 3015 GD, Netherlands
-
Research Site
Panama City, 2723, Panama
-
Research Site
Lima, LIMA 27, Peru
-
Research Site
Lima, LIMA 41, Peru
-
Research Site
Madrid, 08035, Spain
-
Research Site
Valencia, 46010, Spain
-
Research Site
Birmingham, B18 7QH, United Kingdom
-
Research Site
Coventry, CV2 2DX, United Kingdom
-
Research Site
Edinburgh, EH4 2XR, United Kingdom
Conditions
Explore the condition pages connected to this study.